Ephedrine Sulfate

Narcolepsy, Migraine, Catarrh + 13 more

Treatment

20 Active Studies for Ephedrine Sulfate

What is Ephedrine Sulfate

Ephedrine

The Generic name of this drug

Treatment Summary

Pseudoephedrine is a drug related to ephedrine and is extracted from plants that have been used in traditional Eastern medicine for centuries. Pseudoephedrine was first studied in the West in 1889 and its decongestant effect on dogs was discovered in 1927. It works by affecting the sympathetic nervous system, but not as strongly as ephedrine.

Rynatuss

is the brand name

image of different drug pills on a surface

Ephedrine Sulfate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Rynatuss

Ephedrine

1960

36

Effectiveness

How Ephedrine Sulfate Affects Patients

Pseudoephedrine helps to clear up congestion by narrowing blood vessels. It works quickly, but the effects may not last long unless it is taken as a special extended-release medication. Patients should be aware that taking pseudoephedrine can lead to stimulation of the central nervous system.

How Ephedrine Sulfate works in the body

Pseudoephedrine acts as a stimulant on your body, working on alpha and beta adrenergic receptors. This causes your blood vessels to narrow, making it useful for reducing congestion. It is also used to treat long-term erections. Pseudoephedrine also affects the way that hormones and neurotransmitters are transported throughout the body, increasing heart rate, blood pressure, and other bodily functions. It also blocks certain proteins from activating, which helps to reduce inflammation.

When to interrupt dosage

The suggested measure of Ephedrine Sulfate is contingent upon the diagnosed disorder, including Upper Respiratory Tract Infection, Airway secretion clearance therapy and Coughing. The quantity of dosage is contingent upon the method of delivery (e.g. Tablet, extended release or Oral) featured in the table beneath.

Condition

Dosage

Administration

Pharyngitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Migraine

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Narcolepsy

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Myasthenia Gravis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Catarrh

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Acute Bronchitis

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Depression

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Rhinorrhea

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Asthma

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Coughing

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Arthralgia

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Nasal Congestion

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Upper Respiratory Disease

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Hypotension

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Fever

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Hypersensitivity

25.0 mg, , 12.5 mg, 50.0 mg/mL, 10.0 mg, 8.0 mg, 10.0 mg/mL, 30.0 mg, 15.0 mg, 1.5 %, 0.13 mg, 24.0 mg, 1.0 %, 16.0 mg, 2.5 mg/mL, 2.5 mg, 5.0 mg/mL, 5.0 %, 1.8 mg/mL, 7.5 mg, 4.0 mg/mL, 0.75 mg/mL, 0.006 mg/mg, 0.8 mg/mL, 3.75 mg/mL, 47.0 mg/mL, 9.4 mg/mL, 4.7 mg/mL, 0.00534 mg/mg, 0.0046 mg/mg

, Oral, Capsule, Capsule - Oral, Tablet, coated - Oral, Tablet, coated, Tablet, Tablet - Oral, Intramuscular; Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, solution - Intravenous, Injection, Injection - Intramuscular; Intravenous; Subcutaneous, Liquid - Intramuscular; Intravenous; Subcutaneous, Liquid, Solution, Intramuscular; Subcutaneous, Syrup - Oral, Solution - Intramuscular; Intravenous; Subcutaneous, Nasal, Ointment, Ointment - Nasal, Jelly, Jelly - Nasal, Liquid - Oral, Syrup, Injection - Intravenous, Suppository, Suppository - Rectal, Topical, Spray, Spray - Topical, Infiltration; Subcutaneous, Liquid - Infiltration; Subcutaneous, Infiltration, Liquid - Infiltration, Spray - Nasal, Rectal, Bead - Oral, Bead, Liquid - Nasal

Warnings

Ephedrine Sulfate has five contraindications and should not be used while experiencing any of the conditions outlined in the table below.

Ephedrine Sulfate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ephedrine Sulfate.

Common Ephedrine Sulfate Drug Interactions

Drug Name

Risk Level

Description

2,5-Dimethoxy-4-ethylamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylamphetamine can be increased when used in combination with Ephedrine.

2,5-Dimethoxy-4-ethylthioamphetamine

Major

The therapeutic efficacy of 2,5-Dimethoxy-4-ethylthioamphetamine can be increased when used in combination with Ephedrine.

4-Bromo-2,5-dimethoxyamphetamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyamphetamine can be increased when used in combination with Ephedrine.

Acebutolol

Major

The therapeutic efficacy of Acebutolol can be increased when used in combination with Ephedrine.

Amphetamine/Dextroamphetamine

Major

The therapeutic efficacy of Amphetamine can be increased when used in combination with Ephedrine.

Ephedrine Sulfate Toxicity & Overdose Risk

The toxic dose of pseudoephedrine in rats is 2206mg/kg and 726mg/kg in mice. Symptoms of overdose may include dizziness, headache, nausea, vomiting, increased heart rate, chest pain, difficulty urinating, muscle weakness, anxiety, restlessness, insomnia, mental confusion, abnormal heart rhythms, loss of consciousness, seizures, and difficulty breathing. Treatment for an overdose should include supportive care and removal of the drug from the body.

Ephedrine Sulfate Novel Uses: Which Conditions Have a Clinical Trial Featuring Ephedrine Sulfate?

270 active trials are currently investigating the potential of Ephedrine Sulfate to mitigate Allergic Reactions, Migraines, and Eye Ailments.

Condition

Clinical Trials

Trial Phases

Pharyngitis

0 Actively Recruiting

Myasthenia Gravis

15 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 1

Arthralgia

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Hypotension

0 Actively Recruiting

Acute Bronchitis

7 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Hypersensitivity

1 Actively Recruiting

Phase 4

Coughing

0 Actively Recruiting

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Asthma

1 Actively Recruiting

Phase 4

Upper Respiratory Disease

0 Actively Recruiting

Nasal Congestion

0 Actively Recruiting

Catarrh

0 Actively Recruiting

Migraine

13 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Ephedrine Sulfate Reviews: What are patients saying about Ephedrine Sulfate?

4.7

Patient Review

12/12/2008

Ephedrine Sulfate for Bronchitis

4.3

Patient Review

4/9/2009

Ephedrine Sulfate for Bronchitis

I had never tried Bronkaid before, but I decided to give it a shot since I was struggling with my asthmatic bronchitis. I'm really glad I did- within half an hour, I could tell that it was working better than any other over the counter medication I've used for this problem.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ephedrine sulfate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What does ephedrine do to a person?

"The ephedrine alkaloids are weak stimulants that can mildly increase heart rate and blood pressure, as well as relaxing bronchial tissue to ease shortness of breath."

Answered by AI

Is ephedrine sulfate a stimulant?

"Ephedrine is a central nervous system (CNS) stimulant that has been used to prevent low blood pressure during anesthesia, as well as for asthma, narcolepsy, and obesity. While it is not the preferred treatment, it is still used for these purposes."

Answered by AI

How do you take ephedrine sulfate?

"Ephedrine sulfate injection must be diluted with normal saline or 5% dextrose in water before administration as an intravenous bolus to achieve the desired concentration."

Answered by AI

What is ephedrine sulfate used for?

"This drug is indicated for the treatment of allergic disorders such as bronchial asthma. It has been used as a pressor agent for a long time, particularly during spinal anesthesia when hypotension is common."

Answered by AI

Clinical Trials for Ephedrine Sulfate

Image of Lincoln Middle School in Cottage Grove, United States.

Behavioral Interventions for Depression in Students

Any Age
All Sexes
Cottage Grove, OR

The goal of this clinical trial is to learn if two behavioral interventions work to reduce office disciplinary referrals, improve attendance, and reduce depression and anxiety in 7th grade students. This project combines two evidence-based programs-the Inclusive Skill-building Learning Approach (ISLA) for school-wide discipline reform and the Family Check-Up Online (FCU-O) for family-centered support-in an adaptive design to examine the unique and additive effects of these interventions on these child behavior outcomes. The main questions it will answer are: 1. What is the relative efficacy of ISLA vs. School-as-Usual? 2. What is the optimal sequencing of these interventions? 3. Which overall sequence of intervention strategies was most effective? Researchers will compare 6 combinations of these interventions to see which combination and sequencing provides the best student outcomes. School personnel participating in the project will be trained to implement the two interventions at their school. They will answer surveys in the fall, winter, and spring of their year of participation. Parent and Youth participants will complete surveys at baseline and then again 6 months and 12 months later.

Waitlist Available
Has No Placebo

Lincoln Middle School (+12 Sites)

Beth Stormshak, PhD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL

The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.

Waitlist Available
Has No Placebo

Virtual/ No Physical Facility

Candice S Rasa, LCSW

Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA

The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Phase 2
Recruiting

University of California, Los Angeles

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH

In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.

Waitlist Available
Has No Placebo

Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College

Jennifer Emond, PHD

Image of Syracuse VA Medical Center, Syracuse, NY in Syracuse, United States.

Self-Help Intervention for Depression and PTSD

18+
All Sexes
Syracuse, NY

It is important to provide support and resources for the many post-9/11 Veterans with mental health symptoms and poor psychosocial functioning who do not engage in psychotherapy. One of the biggest reasons post-9/11 Veterans do not seek treatment is a preference to handle problems on their own. This study examines a self-help intervention that teaches Veterans healthy coping strategies they can use on their own and how to seek out recovery support services such as mental health treatment or whole-person care if they decide to do so in the future. This study will compare the impact of self-help and standard resources at improving mental health and resource utilization. Two hundred Veterans will complete 6 brief assessments across 40 weeks.

Waitlist Available
Has No Placebo

Syracuse VA Medical Center, Syracuse, NY (+1 Sites)

Robyn L. Shepardson, PhD

Have you considered Ephedrine Sulfate clinical trials?

We made a collection of clinical trials featuring Ephedrine Sulfate, we think they might fit your search criteria.
Go to Trials